Evidence Hub

Extensive empagliflozin-associated Fournier’s gangrene with complete functional recovery – A case report

Rahul Garg, Anmol Thakre

Global Journal of Health Sciences and Research, 2026

Abstract

A 35-year-old diabetic male developed extensive Fournier’s gangrene after 8 months of empagliflozin therapy, representing, to our knowledge, one of the youngest documented cases. The infection progressed rapidly with 80% scrotal involvement within 72 h, necessitating four surgical debridements. Through aggressive staged debridement, negative pressure therapy, and fluorescence-guided tissue assessment, bilateral testicular preservation was achieved despite severe tissue destruction. Complete functional recovery with normal sexual function and no psychological sequelae was documented at 6 months using validated tools. This case demonstrates that extensive sodium-glucose cotransporter-2 inhibitor-associated Fournier’s gangrene can achieve excellent outcomes with early aggressive intervention, challenging existing prognostic assumptions and providing valuable insights for clinical management.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free